William Blair Analyst: DaVita Set to Gain from Medicare Advantage Reimbursement Increase
William Blair analyst Ben Andrew released comments Tuesday morning expressing confidence in DaVita Healthcare (NYSE: DVA), following the victory by health insurers to get the reimbursement for Medicare Advantage increased by 3.3 percent on Monday.
The decision against a reduction in Medicare reimbursements was cited as a reduction in near-term headwinds, while also improving the company's position in the long-term. DaVita was highlighted as one of the "best positioned" companies to benefit from this ruling, and is maintained at an Outperform rating.
Shares of DaVita Healthcare traded up 5.51 percent to $126.52.
Latest Ratings for DVA
|Sep 2016||Raymond James||Upgrades||Market Perform||Outperform|
|Sep 2016||Bank of America||Downgrades||Buy||Neutral|
|Sep 2016||Citigroup||Initiates Coverage on||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.